Alejandro Dorenbaum

Publications

• Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Musson DG, Kramer WG, Foehr ED, Bieberdorf FA, Hornfeldt CS, Kim SS, Dorenbaum A. Clin Ther. 2010; 32 (2): 338-46
• Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, Kakkis ED, Crombez EA, Grange DK, Harmatz P, Lipson MH, Milanowski A, Randolph LM, Vockley J, Whitley CB, Wolff JA, Bebchuk J, Christ-Schmidt H, Hennermann JB. J Pediatr. 2009; 154 (5): 700-7
• Pharmacokinetics of sapropterin in patients with phenylketonuria. Feillet F, Clarke L, Meli C, Lipson M, Morris AA, Harmatz P, Mould DR, Green B, Dorenbaum A, Giovannini M, Foehr E. Clin Pharmacokinet. 2008; 47 (12): 817-25
• Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, Wendel U, Dorenbaum A, Bebchuk J, Christ-Schmidt H, Seashore M, Giovannini M, Burton BK, Morris AA. Am J Med Genet A. 2008; 146A (22): 2851-9
• Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, Levy H. Mol Genet Metab. 2007 Sep-Oct; 92 (1-2): 63-70
• Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum AS, Bebchuk JD, Christ-Schmidt H, Dorenbaum A. Lancet. 2007; 370 (9586): 504-10
• Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A. HIV Med. 2007; 8 (7): 451-6
• The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, Abadie V, Harding CO, Cederbaum S, Dobbelaere D, Smith A, Dorenbaum A. J Inherit Metab Dis. 2007; 30 (5): 700-7
• Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF. Anesthesiology. 2005; 103 (2): 229-40
• Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Watts DH, Balasubramanian R, Maupin RT, Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, Mofenson LM, Culnane M, Cunningham CK. Am J Obstet Gynecol. 2004; 190 (2): 506-16
• The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A, Sullivan JL, Gonzalez-Garcia A, Thorpe E, Rathore M, Gelber RD. J Acquir Immune Defic Syndr. 2004; 36 (3): 800-7
• Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. J Acquir Immune Defic Syndr. 2003; 33 (2): 153-6
• Concentrations of protease inhibitors in cord blood after in utero exposure. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Pediatr Infect Dis J. 2002; 21 (9): 835-8
• Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. J Infect Dis. 2002; 186 (2): 181-8
• Envelope-based HIV vaccines. Donnelly JJ, Barnett SW, Dorenbaum A, Stamatatos L. Science. 2002; 297 (5585): 1277-8; author reply 1277-8
• Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL. JAMA. 2002; 288 (2): 189-98
• When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. Lester P, Chesney M, Cooke M, Weiss R, Whalley P, Perez B, Glidden D, Petru A, Dorenbaum A, Wara D. J Acquir Immune Defic Syndr. 2002; 31 (3): 309-17
• HIV medical advances explored at retrovirus conference Dorenbaum A, Miserez AR. AIDS Policy Law. 2001; 16 (10): 4
• When parents reject interventions to reduce postnatal human immunodeficiency virus transmission. Wolf LE, Lo B, Beckerman KP, Dorenbaum A, Kilpatrick SJ, Weintrub PS. Arch Pediatr Adolesc Med. 2001; 155 (8): 927-33
• Nevirapine: pharmacokinetic considerations in children and pregnant women. Mirochnick M, Clarke DF, Dorenbaum A. Clin Pharmacokinet. 2000; 39 (4): 281-93
• Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A. J Clin Pediatr Dent. 1999; 23 (2): 85-96
• Current applications for the use of nevirapine in HIV 1-infected pregnant women, infants and children Dorenbaum A, Mirochnick M. Journal of HIV Therapy. 1999; 4 (3)
• Cytokine profile of a long-term pediatric HIV survivor with hyper-IgE syndrome and a normal CD4 T-cell count. Seroogy CM, Wara DW, Bluth MH, Dorenbaum A, White C, Durkin HG, Elder ME. J Allergy Clin Immunol. 1999; 104 (5): 1045-51
• Sleep disturbances in children with human immunodeficiency virus infection. Franck LS, Johnson LM, Lee K, Hepner C, Lambert L, Passeri M, Manio E, Dorenbaum A, Wara D. Pediatrics. 1999; 104 (5): e62
• Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group. Hughes W, Dorenbaum A, Yogev R, Beauchamp B, Xu J, McNamara J, Moye J, Purdue L, van Dyke R, Rogers M, Sadler B. Antimicrob Agents Chemother. 1998; 42 (6): 1315-8
• Transmission of HIV-1 in infants born to seropositive mothers: PCR-amplified proviral DNA detected by flow cytometric analysis of immunoreactive beads. Dorenbaum A, Venkateswaran KS, Yang G, Comeau AM, Wara D, Vyas GN. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 15 (1): 35-42
• Recurrent Staphylococcus aureus renal abscess in a child positive for the human immunodeficiency virus. Brandeis JM, Baskin LS, Kogan BA, Wara D, Dorenbaum A. Urology. 1995; 46 (2): 246-8
• Recovery of Malassezia pachydermatis from eight infants in a neonatal intensive care nursery: clinical and laboratory features. Larocco M, Dorenbaum A, Robinson A, Pickering LK. Pediatr Infect Dis J. 1988; 7 (6): 398-401
• Case Report Dorenbaum A, Shearer WT, Abramson SL. Infectious Disease Newsletter. 1987; 6 (5): 38